Call it a draw between Cerexa Inc. and the FDA. On the second of a two-day meeting of the Anti-Infective Drugs Advisory Committee (AIDAC), representatives from the Actavis plc subsidiary saw combination antibacterial candidate ceftazidime-avibactam (CAZ/AVI) heartily endorsed to treat two types of serious infections caused by resistant gram-negative pathogens.